Cellsway
Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) from blood.
Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) from blood.
Cellsway is a UK-based biotechnology startup established in 2020 with the mission to revolutionize cancer diagnosis and management through their cutting-edge liquid biopsy platform. Leveraging patent-pending microfluidic technology, the company focuses on isolating and enumerating Circulating Tumor Cells (CTCs) from blood samples, offering a non-invasive and efficient method for cancer diagnostics and research.
With a recent $389.97K investment from Invest 101, Technology & Innovation Fund in 22 August 2024, Cellsway aims to further develop and commercialize their flagship product. Capitalizing on their expertise cultivated at Mikro Biyosistemler Inc., the company aspires to set the industry standard in cancer monitoring and treatment. Operating at the intersection of biotechnology and healthcare, Cellsway demonstrates potential for significant impact in the fight against cancer.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $389.97K | 2 | Invest 101, Technology & Innovation Fund | 22 Aug 2024 |
| Grant | €1.00M | 2 |
|
09 Oct 2023 |
| Seed Round | €200.00K | 1 |
|
09 Oct 2023 |
| Convertible Note | $100.00K | 1 | Teknoloji Yatirim | 31 Jul 2023 |
| Convertible Note | $150.00K | 1 | Teknoloji Yatirim | 12 Aug 2022 |
We care about your data, and we'd love to use cookies make your experience better.
